維亞生物(01873.HK):擬發行全部或部分代價股份,或支付現金1000萬美元代替
格隆匯 12 月 23日丨維亞生物(01873.HK)公佈,有關收購SYNthesis med chem (HongKong) Limited的全部股權,代價約為8000萬美元.作為收購事項代價的一部分,公司可於完成時向賣方發行865.47萬股代價股份,而有關代價股份將根據一般授權發行。收購公告中亦披露,公司有權向賣方支付1000萬美元現金以代替發行代價股份。
公司其後於2020年12月18日宣佈,其擬發行2.8億美元的有擔保可轉換債券,而有關債券可轉換為1.87億股股份(假設按初步轉換價(定義見相關公告)悉數轉換)。經計及於2020年7月10日根據一般授權配售1.3億股股份,公司於發行有擔保可轉換債券後,將不會有足夠一般授權以於完成時發行代價股份。有見及此,公司擬根據將向股東尋求的特別授權發行全部或部分代價股份,或依賴其於協議下的權利向賣方支付1000萬美元現金以代替發行代價股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.